Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.

@article{Hanada2012RandomizedSO,
  title={Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.},
  author={Kenji Hanada and Takumi Higuma and Fumie Nishizaki and Takanori Sukekawa and Takashi Yokota and Masahiro Yamada and Shin Saito and Motoi Kushibiki and Koichi Oikawa and Naoki Abe and Hirofumi Tomita and Tomohiro Osanai and Ken Okumura},
  journal={Circulation journal : official journal of the Japanese Circulation Society},
  year={2012},
  volume={76 2},
  pages={439-45}
}
BACKGROUND It is still controversial whether intravenous administration of β-blocker in the very acute phase of acute myocardial infarction (AMI) is beneficial. Landiolol is an ultra-short-acting β-blocker that has less effect on blood pressure, but little is known about its efficacy and safety for patients with AMI undergoing primary percutaneous coronary intervention (PCI). METHODS AND RESULTS A consecutive 96 patients with AMI not manifesting cardiogenic shock were prospectively randomized… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Similar Papers

Loading similar papers…